Beyond Bulls & Bears

PODCAST: Market Movements: Outlook and Valuations for US Equities
Equity

PODCAST: Market Movements: Outlook and Valuations for US Equities

Franklin Equity Group’s Evan McCulloch, Grant Bowers and Jonathan Curtis take an in-depth look at US equities following the latest market movements. They also share their outlooks for the technology and biotech sectors in particular.

Assessing Potential US Health Care Reforms Ahead of an Election Year
Equity

Assessing Potential US Health Care Reforms Ahead of an Election Year

Franklin Equity Group’s Evan McCulloch discusses why we might see US legislation on drug pricing before the 2020 US Presidential Election. He also explains why he’s optimistic about the outlook for the biotechnology and pharmaceutical industries.

New Innovation Spurring a Biotech Rejuvenation
Equity

New Innovation Spurring a Biotech Rejuvenation

“We’ve seen medical advancements and breakthroughs in drugs and health care technology reach unprecedented levels in recent years. We foresee this potentially long cycle of innovation persisting.” – Evan McCulloch, Franklin Equity Group

The Politics of Health Care
Equity

The Politics of Health Care

“There have been huge breakthroughs in gene therapy as well as in the area of cancer treatment. Major waves of innovation are a reflection of the exponential leaps in basic research and our understanding of human biology, which are now bearing fruit.” - Evan McCulloch, Franklin Equity Group

3 Reasons Why Investors Should Ignore Political Threats to Biotech
Equity

3 Reasons Why Investors Should Ignore Political Threats to Biotech

Given that the United States is considered a world leader in pharmaceutical innovation, we think it’s unlikely that politicians would want to impede the profit motivation of innovation and potentially severely impair the industry’s growth.

The Politics—and Potential—of US Biotech
Equity

The Politics—and Potential—of US Biotech

We do not believe anyone wants to ‘kill the golden goose,’ however, and even politicians would likely admit that draconian price controls would reduce the incentive for investing in drug research and development, which has resulted in many breakthrough therapies in the last several years.

In the Know: What’s Ailing US Biotech?
Equity

In the Know: What’s Ailing US Biotech?

Even if Hillary Clinton’s prescription plan, as we currently understand it, did ultimately pass, in my view the impact would be very manageable for the (biotech) sector.

Biotech Boom, or Bubble?

Biotech Boom, or Bubble?

A Biotech and Pharmaceutical Prescription

A Biotech and Pharmaceutical Prescription